Steven Cohen's SRPT Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 510,908 shares of Sarepta Therapeutics, Inc. (SRPT) worth $9.18 M, representing 0.01% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in SRPT, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2015, adding 1.47 M shares. Largest reduction occurred in Q4 2016, reducing 1.92 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +510,908 | New Buy | 510,908 | $17.97 |
| Q1 2026 | -207,513 | Sold Out | 0 | $0.00 |
| Q4 2025 | +207,513 | New Buy | 207,513 | $21.52 |
| Q4 2024 | -36,855 | Sold Out | 0 | $0.00 |
| Q3 2024 | -12,058 | Reduce 24.65% | 36,855 | $124.89 |
| Q2 2024 | +48,913 | New Buy | 48,913 | $158.00 |
| Q4 2023 | -307,343 | Sold Out | 0 | $0.00 |
| Q3 2023 | -22,026 | Reduce 6.69% | 307,343 | $121.22 |
| Q2 2023 | +280,913 | Add 579.73% | 329,369 | $114.52 |
| Q1 2023 | -655,299 | Reduce 93.11% | 48,456 | $137.83 |
| Q4 2022 | -148,145 | Reduce 17.39% | 703,755 | $129.58 |
| Q3 2022 | +426,393 | Add 100.21% | 851,900 | $110.54 |
| Q2 2022 | -1.02 M | Reduce 70.60% | 425,507 | $74.96 |
| Q1 2022 | +296,002 | Add 25.71% | 1.45 M | $78.12 |
| Q4 2021 | -694,791 | Reduce 37.64% | 1.15 M | $90.05 |
| Q3 2021 | +1.43 M | Add 340.99% | 1.85 M | $92.48 |
| Q2 2021 | +279,614 | Add 201.18% | 418,600 | $77.74 |
| Q1 2021 | +138,986 | New Buy | 138,986 | $74.53 |
| Q1 2020 | -344,710 | Sold Out | 0 | $0.00 |
| Q4 2019 | -351,975 | Reduce 50.52% | 344,710 | $129.04 |
| Q3 2019 | +696,685 | New Buy | 696,685 | $75.32 |
| Q2 2019 | -260,790 | Sold Out | 0 | $0.00 |
| Q1 2019 | +182,897 | Add 234.81% | 260,790 | $119.19 |
| Q4 2018 | +12,123 | Add 18.43% | 77,893 | $109.12 |
| Q3 2018 | -199,991 | Reduce 75.25% | 65,770 | $161.52 |
| Q2 2018 | +265,761 | New Buy | 265,761 | $132.18 |
| Q1 2018 | -579,757 | Sold Out | 0 | $0.00 |
| Q4 2017 | -1.07 M | Reduce 64.76% | 579,757 | $55.64 |
| Q3 2017 | -380,131 | Reduce 18.77% | 1.65 M | $45.36 |
| Q2 2017 | +1.22 M | Add 152.14% | 2.03 M | $33.71 |
| Q1 2017 | -564,299 | Reduce 41.26% | 803,300 | $29.60 |
| Q4 2016 | -1.92 M | Reduce 58.36% | 1.37 M | $27.43 |
| Q3 2016 | +536,687 | Add 19.53% | 3.28 M | $61.41 |
| Q2 2016 | -214,631 | Reduce 7.25% | 2.75 M | $19.07 |
| Q1 2016 | +586,531 | Add 24.69% | 2.96 M | $19.52 |
| Q4 2015 | +1.47 M | Add 160.96% | 2.38 M | $38.58 |
| Q3 2015 | -26,230 | Reduce 2.80% | 910,370 | $32.11 |
| Q2 2015 | -765,600 | Reduce 44.98% | 936,600 | $30.43 |
| Q1 2015 | +150,900 | Add 9.73% | 1.7 M | $13.28 |
| Q4 2014 | +1.32 M | Add 582.49% | 1.55 M | $14.47 |
| Q3 2014 | -44,800 | Reduce 16.46% | 227,300 | $21.10 |
| Q2 2014 | +272,100 | Add 0.00% | 272,100 | $29.79 |
Steven Cohen's Sarepta Therapeutics Investment FAQs
Steven Cohen first purchased Sarepta Therapeutics, Inc. (SRPT) in Q2 2014, acquiring 272,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Sarepta Therapeutics, Inc. (SRPT) for 42 quarters since Q2 2014.
Steven Cohen's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q4 2015, adding 2,375,700 shares worth $91.66 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 510,908 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $9.18 M.
As of the Q2 2026 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 3,284,287 shares, as reported at the end of Q3 2016.